Charles Sherwood - Anika Therapeutics CEO and President and Director
| ANIK Stock | USD 25.90 0.11 0.43% |
CEO
Dr. Charles H. Sherwood, Ph.D., is no longer Chief Executive Officer, Director of Anika Therapeutics, Inc effective on March 9, 2018. Dr. Sherwood previously served as Anika Therapeutics Chief Operating Officer beginning in June 2001, Vice President of Research and Development beginning in April 2000, and Vice President of Process Development and Engineering beginning in April 1998. Dr. Sherwood served as a consultant to Anika Therapeutics from January 1998 to April 1998. From 1995 to 1997, Dr. Sherwood was Senior Director of Medical Device Research and Development for Chiron Vision. In April 1995, Chiron Vision acquired IOLAB Corporationrationration, a division of Johnson Johnson where Dr. Sherwood had been Executive Director of Research and Development from 1993 to 1995, Director of Materials Characterization from 1989 to 1993, and ManagerSection Head from 1982 to 1989. Dr. Sherwood was also a parttime faculty member in the Department of Chemistry at the California State Polytechnic University, Pomona, California from 1984 to 1987. Dr. Sherwood received a B.S. in Chemical Engineering from Cornell University, and an M.S. and Ph.D. in Polymer Science and Engineering from the University of Massachusetts, Amherst. Dr. Sherwood also received a Certificate in Management from Claremont Graduate School.
| Age | 69 |
| Address | 32 Wiggins Avenue, Bedford, MA, United States, 01730 |
| Phone | 781 457 9000 |
| Web | https://www.anika.com |
Anika Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0236) % which means that it has lost $0.0236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3321) %, meaning that it created substantial loss on money invested by shareholders. Anika Therapeutics' management efficiency ratios could be used to measure how well Anika Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.3 this year. Return On Capital Employed is expected to rise to -0.1 this year. At this time, Anika Therapeutics' Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 3.6 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 148 M.Management Performance
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.0236 |
Anika Therapeutics Leadership Team
Elected by the shareholders, the Anika Therapeutics' board of directors comprises two types of representatives: Anika Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anika. The board's role is to monitor Anika Therapeutics' management team and ensure that shareholders' interests are well served. Anika Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anika Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Sherwood, CEO and President and Director | ||
| James Chase, Senior Marketing | ||
| Bart Bracy, VP Americas | ||
| Lisa Funiciello, Vice Resources | ||
| Mark Namaroff, Executive Communications | ||
| Dana Alexander, COO | ||
| Raymond Land, Independent Director | ||
| Richard Hague, Chief Commercial Officer | ||
| Susan Vogt, Independent Director | ||
| Michael Levitz, CFO VP | ||
| Ben Joseph, Vice Development | ||
| Joseph Darling, President | ||
| Sylvia Cheung, CFO, Principal Accounting Officer, Treasurer and Secretary | ||
| Joseph Bower, Lead Independent Director | ||
| Jeffrey Thompson, Independent Director | ||
| David Colleran, Gen VP | ||
| David JD, General VP | ||
| Steven Wheeler, Independent Director | ||
| Thomas Finnerty, Chief Human Resource Officer | ||
| Stephen Mascioli, Chief Medical Officer | ||
| Edward Ahn, Chief Technology and Strategy Officer | ||
| Ian McLeod, VP Officer | ||
| Charles III, VP Counsel | ||
| Glenn Larsen, Independent Director | ||
| Anne Nunes, VP Operations | ||
| Cheryl Blanchard, Independent Director |
Anika Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anika Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.0236 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | 0.57 % | ||||
| Current Valuation | 336.65 M | ||||
| Shares Outstanding | 14.85 M | ||||
| Shares Owned By Insiders | 3.25 % | ||||
| Shares Owned By Institutions | 94.33 % | ||||
| Number Of Shares Shorted | 770.4 K | ||||
| Price To Earning | 42.30 X |
Pair Trading with Anika Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anika Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anika Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Anika Stock
| 0.8 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.77 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
Moving against Anika Stock
| 0.65 | GILD | Gilead Sciences Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Anika Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anika Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anika Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anika Therapeutics to buy it.
The correlation of Anika Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anika Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anika Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anika Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Anika Stock analysis
When running Anika Therapeutics' price analysis, check to measure Anika Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anika Therapeutics is operating at the current time. Most of Anika Therapeutics' value examination focuses on studying past and present price action to predict the probability of Anika Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anika Therapeutics' price. Additionally, you may evaluate how the addition of Anika Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Anika Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (5.64) | Revenue Per Share 11.372 | Quarterly Revenue Growth 0.085 | Return On Assets (0.02) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.